At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 12 target
Drug / intervention
KD-496biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
In Brief
A Phase 1 clinical trial evaluating KD-496 for Gastric Cancer and 2 related conditions. Not yet recruiting, targeting 12 participants across 1 site.
Detailed Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Pancreatic Cancer, Solid Tumor
CountriesChina
CollaboratorsKAEDI
Timeline
Phase 1Not Yet Recruiting
202420252026
Enrollment StartNov 2023
First PostedNov 2023
Primary CompletionJun 2026
TodayJul 2026
Study CompletionNov 2026
First PostedNov 18, 2023
Enrollment StartNov 16, 2023
Primary CompletionJun 30, 2026
Study CompletionNov 15, 2026
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 2.6 years ago
Interventions
KD-496biological
Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells